The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis

Oral Oncology

Volumn 46, Issue 4, 2010, Pages 302-306

  Chiu, Yu Wei ^a,b   Tu, Hsi Feng ^a   Wang, I Kai ^a,b   Wu, Cheng Hsien ^a,b   Chang, Kuo Wei ^a,b   Liu, Tsung Yun ^b   Kao, Shou Yen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Carcinogenesis; Genetic polymorphism; Oral squamous cell carcinoma; Osteopontin; Risk

Indexed keywords

GENOMIC DNA; OSTEOPONTIN; SCLEROPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TAIWAN; TUMOR GROWTH;

CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM PROTEINS; OSTEOPONTIN; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TAIWAN;

EID: 77949568437     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.01.018     Document Type: Article

References (27)

1. Chellaiah M.A., Kizer N., Biswas R., et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14 1 (2003) 173-189
2. Ishijima M., Rittling S.R., Yamashita T., et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193 3 (2001) 399-404
3. Patarca R., Freeman G.J., Singh R.P., et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 170 1 (1989) 145-161
4. Wai P.Y., and Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 121 2 (2004) 228-241
5. El-Tanani M.K., Campbell F.C., Kurisetty V., Jin D., McCann M., and Rudland P.S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17 6 (2006) 463-474
6. D′Alfonso S., Barizzone N., Giordano M., et al. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52 2 (2005) 539-547
7. Hummelshoj T., Ryder L.P., Madsen H.O., Odum N., and Svejgaard A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 43 7 (2006) 980-986
8. Mochida S., Hashimoto M., Matsui A., et al. Genetic polymorphism in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 313 4 (2004) 1079-1085
9. Rangaswami H., Bulbule A., and Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Biol 16 2 (2006) 79-87
10. Das R., Mahabeleshwar G.H., and Kundu G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279 12 (2004) 11051-11064
11. Lin Y.H., and Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276 49 (2001) 46024-46030
12. Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 1 Pt 1 (2004) 184-190
13. Donati V., Boldrini L., Dell'Omodarme M., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11 18 (2005) 6459-6465
14. Forootan S.S., Foster C.S., Aachi V.R., et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118 9 (2006) 2255-2261
15. Department of Health EY ROCT. Ranking of cancer mortality in Taiwan; 2007.
16. Department of Health EY ROCT. Cancer registry annual report in Taiwan area; 2007.
17. Zhao J.H., Curtis D., and Sham P.C. Model-free analysis and permutation tests for allelic associations. Human Hered 50 2 (2000) 133-139
18. Zhao J.H., Lissarrague S., Essioux L., and Sham P.C. GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics (Oxford, England) 18 12 (2002) 1694-1695
19. Zhao J.H., and Sham P.C. Faster haplotype frequency estimation using unrelated subjects. Human Hered 53 1 (2002) 36-41
20. Zhao J.H., and Sham P.C. Generic number systems and haplotype analysis. Comput Meth Programs Biomed 70 1 (2003) 1-9
21. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 6835 (2001) 342-348
22. Xuan J.W., Hota C., Shigeyama Y., D'Errico J.A., Somerman M.J., and Chambers A.F. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 57 4 (1995) 680-690
23. Teti A., Farina A.R., Villanova I., et al. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer 77 1 (1998) 82-93
24. Celetti A., Testa D., Staibano S., et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 11 22 (2005) 8019-8027
25. Muramatsu T., Shima K., Ohta K., et al. Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett 217 1 (2005) 87-95
26. Kita Y., Natsugoe S., Okumura H., et al. Expression of osteopontin in oesophageal squamous cell carcinoma. Br J Cancer 95 5 (2006) 634-638
27. Barnes G.L., Javed A., Waller S.M., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63 10 (2003) 2631-2637